Optimisation of anti-psychotic therapeutics: A balancing act?

British Journal of Pharmacology

Volumn 151, Issue 2, 2007, Pages 161-162

  Lawrence, A J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

5 HT 1A receptor; Anti psychotic; D 2 receptor; F15063; Schizophrenia

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; ARIPIPRAZOLE; BIFEPRUNOX; CLOZAPINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 4 RECEPTOR; F 15063; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; UNCLASSIFIED DRUG; ZIPRASIDONE;

CLINICAL TRIAL; COGNITIVE DEFECT; DOPAMINERGIC ACTIVITY; DRUG ANTAGONISM; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENTAL HEALTH CENTER; NEGATIVE SYNDROME; NONHUMAN; POSITIVE SYNDROME; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TRACTION THERAPY; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZOFURANS; BENZYLAMINES; CYCLOPENTANES; HUMANS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 34248572635     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707164     Document Type: Review

References (10)

1. 4 partial agonist properties: activity in models of positive symptoms of schizophrenia. Br J Pharmacol 151, 253-265 (this issue).
2. 4 partial agonist properties: activity in models of cognition and negative symptoms. Br J Pharmacol 151, 266-277 (this issue).
3. Hall J, Whalley HC, Job DE, Baig BJ, McIntosh AM, Evans KL et al. (2006). A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci 9: 1477-1478.
4. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
5. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR et al. (2005). DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310: 1187-1191.
6. 4 partial agonist properties: in vitro receptor affinity and efficacy profile. Br J Pharmacol 151, 237-252 (this issue).
7. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS et al. (2006). Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 163: 2080-2089.
8. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT (2006). Neurobiology of schizophrenia. Neuron 52: 139-153.
9. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV et al. (2002). Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 71: 337-348.
10. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M et al. (2005). The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66: 1122-1129.